Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.7 Supplemental Indenture 5.75% 2022 Notes
- 4.9 Supplemental Indenture 7.25% 2022 Notes
- 4.12 Supplemental Indenture 2023 Notes
- 4.15 Supplemental Indenture 2025 Notes
- 10.28 Novartis License Agreement
- 10.32 Final Indemnification Agreement
- 10.33 Executive Employment Agreement
- 10.18.1 Biospecifics Technologies Amendment to 2ND Development and License Agreement
- 21.1 Subsidiaries
- 23.1 Consent of PWC LLP
- 23.2 Consent of Deloitte and Touche LLP
- 24.1 Power of Attorney
- 31.1 CEO Section 302 Certification
- 31.2 CFO Section 302 Certification
- 32.1 CEO Section 906 Certification
- 32.2 CFO Section 906 Certification
- Download Excel data file
- View Excel data file
Related press release
ENDPQ similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-194253 and 333-204958 on Form S-8, and No. 333-204657 on Form S-3 of Endo International plc of our report dated February 28, 2014 (June 2, 2015 as to the effects of the discontinued operations discussed in Note 3), relating to the consolidated financial statements, comprised of the consolidated statements of operations, comprehensive loss, shareholders’ equity, and cash flows for the year ended December 31, 2013, and the consolidated financial statement schedule for the year ended December 31, 2013, of Endo Health Solutions Inc. (now known as Endo International plc) and subsidiaries, appearing in this Annual Report on Form 10-K of Endo International plc for the year ended December 31, 2015.
/s/ DELOITTE & TOUCHE LLP
Philadelphia, Pennsylvania
February 29, 2016